



Europass Curriculum Vitae

||

Personal information

First name(s) / Surname(s)

Orietta Gandini

Address(es)

Department of Molecular Medicine, Viale Regina Elena 324, 00161, Rome, Italy

Telephone(s)

06 49979506 -06 4451286

Fax(es)

E-mail

Orietta.gandini@uniroma1.it

Nationality

italian

Gender

female

Occupational field

Endocrinology

Oncology

Work experience

Dates

1992-1995

Occupation or position held

Visiting Associated

Name and address of employer

Laboratory of Reproductive and Developmental Toxicology, (Dr Kenneth Korach)
National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina USA

Sector

Endocrinology

Dates

2004-

Occupation or position held

Assistant professor

Main activities and responsibilities

Count and characterization of circulating tumor cells in patients with solid tumors
Count of circulating endothelial cells in obese patients.

Name and address of employer

Sapienza University of Rome

Sector

General pathology

Education and training

Dates
Title of qualification awarded
Name and type of organisation providing education and training

1988
M.D
Sapienza" University, Roma, Italy

Dates
Title of qualification awarded
Name and type of organisation providing education and training

1993
Residency in Endocrinology
Sapienza" University, Roma, Italy

Dates
Title of qualification awarded
Name and type of organisation providing education and training

2011:
Master In Prevenzione e Assistenza a Sovrappeso, Obesita' e Disturbi dell'alimentazione
Sapienza" University, Roma, Italy

Personal skills and competences

Organizational skills, determination, self-motivated
Leadership (have been responsible for a team of 10 people)
Sense of organization
Good experience in project and team management

Computer skills and competences

Good command of Microsoft Office™ tools (Word™, Excel™ and PowerPoint™)

Mother tongue(s)

Italian

Other language(s)

English

Self-assessment

European level (*)

Language

Language

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
B2	B1	B2	B1	B1

(*) [Common European Framework of Reference for Languages](#)

Scientific publications

Gradilone A, Greco C, Gazzaniga P, Vercillo R, Napolitano M, **Gandini O**, Mattei F, Frati L, Aglianò AM. Bax gene expression in melanoma metastases. Journal of Investigative Dermatology 106, 382 1996, Feb.,

Gazzaniga P, Gradilone A, Vercillo R, **Gandini O**, Silvestri I, Napolitano M, Albonici L, Vincenzoni A, Gallucci M, Frati L and Aglianò AM. bcl 2/bax mRNA expression ratio as prognostic factor in low grade urinary bladder cancer. Int. J. Cancer 69: 100-104 1996

Gradilone A, Vercillo R, Napolitano M, Cardinali G, Gazzaniga P, Silvestri I, **Gandini O**, Tomao S and Aglianò AM. Prevalence of human papillomavirus, cytomegalovirus and Epstein-Barr virus in the cervix of healthy women. J. Med. Virol. Sep 50, 1-4, 1996,

Kohn H, Bocchinfuso WP, **Gandini O**, Curtis SW and Korach KS.
Mutational analysis of the estrogen receptor ligand-binding domain: influences of ligand structure and stereochemistry on transactivation. J. Mol. Endocrinol. 16: 277-285 1996

Gandini O, Kohn H, Curtis SW and Korach KS. Two transcription activation functions in the amino terminus of the mouse estrogen receptor interact with the carboxy terminus. Steroids 62: 508-515, 1997

- Aglianò A.M., Naso G., Silvestri I., Gradilone A., Vercillo R., Napolitano M., Gazzaniga P., **Gandini O.**, Realacci M., Santangelo C., Saccani G., Manzari V. and Frati L. Involvement of bcl-2 and bax gene expression in apoptosis and differentiation of the non-tumorigenic murine hematopoietic cell line, 32DC13(G) *Int. J. Oncology* 11: 1217-1277, 1997
- Gazzaniga P., Vercillo R., Gradilone A., Ida Silvestri I., **Gandini O.**, Napolitano M., Giuliani L., Fioravanti A., Gallucci M., Agliano' AM. Prevalence of Papillomavirus, Epstein-Barr virus, Cytomegalovirus and Herpes Simplex virus type 2 in urinary bladder cancer. *J. Med. Virol.*, Aug. 55 (4) : 262-267, 1998
- P. Gazzaniga, A. Gradilone, I. Silvestri, **O. Gandini**, M. Napolitano, R. Vercillo, A. Vincenzoni, M. Gallucci, L. Frati, A.M. Agliano' High levels of TGF- β mRNA may predict local relapses in low stage urinary bladder cancer. *Eur. J. Cancer*, Vol 34,6: 934-936, 1998.
- Paola Gazzaniga, Angela Gradilone, Ida Silvestri, **Orietta Gandini**, Laura Giuliani, Andrea Vincenzoni, Michele Gallucci, Luigi Frati, Anna Maria Agliano' Variable levels of bcl-2, bcl-X and bax mRNA in bladder cancer progression *Oncology Reports*, 5: 901-904, 1998
- Paola Gazzaniga, **Orietta Gandini**, Angela Gradilone, Ida Silvestri, Laura Giuliani, Massimo Magnanti, Michele Gallucci, Gloria Saccani, Luigi Frati, Anna Maria Agliano' Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses *Int. J. Oncology*, June 14(6) 1123-1127, 1999
- Gandini O.**, Celi F.S., Magnanti M., Gazzaniga P., Silvestri I., Conti B., Giuliani L., Mentuccia D., Aglianò A.M.: "Rapid, simple inexpensive step facilitates RNA extraction from whole blood cell". *Laboratory Investigation*, Dec 12 1731-32., 1999
- Magnanti M, Giuliani L, **Gandini O**, Gazzaniga P, Santiemma V, Ciotti M, Saccani G, Frati L, Agliano' AM. Follicle-stimulating hormone, testosterone, and hypoxia differentially regulate UDP-glucuronosyl-transferase 1 isoforms expression in rat sertoli and peritubular myoid cells *J. Steroid Biochem Mol Biol*, Sep. 2000 74/3-4
- Magnanti M., Gismondi A., **Gandini O.**, Rossi F.M., Michetti P.M., Santiemma V., Morrone S.: Integrin pattern and effect on contraction in cultured peritubular myoid cells. *Am J Reprod Immunol* 2000, 45:21-27
- Gazzaniga P, **Gandini O**, Giuliani L, Magnanti M, Gradilone A, Silvestri I, Gianni W, Gallucci M, Frati L and Agliano' AM Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. *Cl. Cancer Res.*, 2001, 7: 577-583
- Magnanti M , **Gandini O**, Giuliani L, Gazzaniga P, Marti HH, Gradilone A, Frati L., Agliano AM, Gassmann M. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells *Blood* , 1; 98(9): 2872-4, 2001
- A. Gradilone, P. Gazzaniga, I. Silvestri, **O. Gandini**, L. Trasatti, S. Lauro, L. Frati, AM Aglianò Detection of CK-19, CK-20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease *Oncol. Rep.*, 10 (1): 217-222, 2003
- Paola Gazzaniga, Angela Gradilone, Laura Giuliani, Orietta Gandini, Ida Silvestri, Italo Nofroni, Gloria Saccani, Luigi Frati, Anna Maria Agliano' Expression and prognostic significance of livin, survivin and other apoptosis related genes in the progression of superficial bladder cancer. *Annals Oncol* 2003 14:85-90
- Orietta Gandini**, Letizia Luci, Antonio Stigliano Rossana Lucera, Franco Di Silverio, Vincenzo Toscano, Maria Rosaria Cardillo. Is DD3 a new prostate-specific gene? *Anticancer research*, 2003, 23: 305-308
- Gandini, Orietta**; Santulli, Maria; Cardillo, Maria Rosaria; Stigliano, Antonio; Toscano, Vincenzo Correspondence Re: J. B. de Kok et al., DD3, a Very Sensitive and Specific Marker to Detect Prostate Tumors. *Cancer Res.*, 62: 2695-2698, 2002. *Cancer Res*, 2003; 63 (15)
- L. Giacomelli, W. Gianni, C. Belfiore, **O. Gandini**, L. Repetto, A. Filippini, L. Frati, A.M. Aglianò and P. Gazzaniga Persistence of EGFR and IL-10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. *Clin Cancer Res*, , 2003, 9: 2678-2682
- Marchese R, Muleti A, Brozzetti S, **Gandini O**, Brunetti E, French D. Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer. *Br J Cancer*. 2004, Jun 1;90(11):2243.
- Gazzaniga P, Nofroni I, **Gandini O**, Silvestri I, Frati L, Agliano AM, Gradilone A. Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. *Oncol Rep*. 2005 Nov;14(5):1199-202
- Gazzaniga P, Silvestri I, Gradilone A, Scarpa S, Morrone S, **Gandini O**, Gianni W, Frati L, Agliano AM. Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. *Anticancer Drugs*. 2007 Feb;18(2):179-85.

- Gradilone A, Silvestri I, Scarpa S, Morrone S, **Gandini O**, Pulcinelli FM, Gianni W, Frati L, Agliano AM, Gazzaniga P. Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines. *Oncol Rep*. 2007 Apr;17(4):823-8
- A Stigliano, **O Gandini**, L Cerquetti, P Gazzaniga, S Misiti, S Monti, A Gradilone, P Falasca, M. Poggi, E Brunetti, A M Aglianò and V Toscano. Increase mln64 and cyp17 expression are associated with high staged prostate cancer. *Journal of Endocrinology* 2007 vol 194 55-61
- Angela Gradilone, Paola Gazzaniga, Emanuele Cigna, Fortunata Vasaturo, Bruno Vincenzi, **Orietta Gandini**, Ida Silvestri, Diego Ribuffo, Susanna Scarpa, Nicolò Scuderi, and Anna Maria Aglianò. Fibronectin and Laminin expression in sentinel lymph nodes of melanoma patients. *British Journal of Dermatology* 2007 Vol. 157, (2) 398-401
- Angela Gradilone, Fabio Maria Pulcinelli, Lavinia Vittoria Lotti, Elisabetta Trifirò, Simone Martino, **Orietta Gandini**, Walter Gianni, Luigi Frati, Anna Maria Aglianò and Paola Gazzaniga. "Celecoxib upregulates MRP-4 and MRP-5 in colon cancer: lack of synergy with standard chemotherapy". *Current Cancer Drug Targets* 2008 Aug;8(5):414-20.
- Gazzaniga P, Naso G, Gradilone A, Cortesi E, **Gandini O**, Gianni W, Fabbri MA, Vincenzi B, di Silverio F, Frati L, Aglianò AM, Cristofanilli M. Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. *Int J Cancer*. 2010 May 15;126(10):2437-47.
- A. Gradilone, G, Naso, C. Raimondi, E. Cortesi, **O. Gandini**, B. Vincenzi, R. Saltarelli, E. Chiapparino, F. Spremberg, M. Cristofanilli, L. Frati, A.M. Aglianò, and P. Gazzaniga. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization. *Annals Oncol*, 2011,22;86-92
- Gazzaniga P, Naso G, Raimondi C, Gradilone A, Palazzo A, **Gandini O**, Petracca A, Nicolazzo C, Cortesi E, Frati L. Circulating tumor cells count and characterization in a male breast cancer: from bench to bedside. *Cancer Biol Ther*, 2011 12(5):379-82
- A. Gradilone, G, Naso, C. Raimondi, E. Cortesi, **Gandini O.**, B. Vincenzi, R. Saltarelli, E. Chiapparino, F. Spremberg, M. Cristofanilli, L. Frati, A.M. Aglianò, And P. Gazzaniga (2011). Circulating Tumor Cells (CTCs) In Metastatic Breast Cancer (Mbc): Prognosis, Drug Resistance And Phenotypic Characterization. *Annals Of Oncology*, Vol. 22; P. 86-92, Issn: 0923-7534
- Gazzaniga P, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, **Gandini O.**, Nicolazzo C, Petracca A, Vincenzi B, Farcomeni A, Gentile V, Cortesi E, Frati L. (2012). Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. *ANNALS OF ONCOLOGY*, vol. 23; p. 2352-2356, ISSN: 0923-7534, doi: 10.1093/annonc/mdr619A.
- Gazzaniga P, Gianni W, Raimondi C, Gradilone A, Lo Russo G, Longo F, **Gandini O**, Tomao S, Frati L. Circulating tumor cells in high-risk nonmetastatic colorectal cancer. *Tumour Biol*. 2013 Mar 29.
- Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, **Gandini O**, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff *J Cancer Res Clin Oncol*. 2013 Aug;139(8):1411-6. Epub 2013 Jun 5
- Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, **Gandini O**, Mastromartino M, Del Bene G, Prete A, Longo F, Cortesi E, Gazzaniga P. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. *Sci Rep*. 2016 Aug 24;6:31726.

FIRMATO

ORietta GANDINI